[CAS NO. 7177-50-6] Nafcillin sodium monohydrate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [7177-50-6]

Catalog

HY-B0555A

Brand

MCE

CAS

7177-50-6

DESCRIPTION [7177-50-6]

Overview

MDL	-
Molecular Weight	454.47
Molecular Formula	C21H23N2NaO6S
SMILES	O=C([C@@H]1N(C2=O)[C@]([C@@H]2NC(C(C3=CC=CC=C3C=C4)=C4OCC)=O)([H])SC1(C)C)O[Na].O

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

Nafcillin sodium monohydrate, an antibiotic , is a reversible inhibitor of β-lactamase . Nafcillin sodium monohydrate can be used for the research of staphylococcal infections ^[1] ^[2] .

IC50 & Target

Bacteria ^[1]

In Vivo

Nafcillin sodium monohydrate (100 mg/kg; s.c.) exhibits bactericidal activity against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA), with MIC s of 0.5 μg/mL and 64.0 μg/mL for S. aureus strains Xen-29 and Xen-1, respectively, in mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CD-1 female mice (20-25 g), with MRSA- and MSSA-infected ^[3]
Dosage:	100 mg/kg
Administration:	Subcutaneous injection
Result:	Protected 100% of the healthy mice with MSSA infections.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00428844	Cubist Pharmaceuticals LLC	Osteomyelitis	June 26, 2007	Phase 2
NCT04775953	National Institute of Allergy and Infectious Diseases (NIAID)	Staphylococcal Bacteraemia	April 22, 2021	Phase 2
NCT01922011	Cubist Pharmaceuticals LLC	Acute Hematogenous Osteomyelitis	September 13, 2013	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 220.04 mM ; Need ultrasonic)

H ₂ O : 1 mg/mL ( 2.20 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2004 mL	11.0018 mL	22.0037 mL
5 mM	0.4401 mL	2.2004 mL	4.4007 mL
10 mM	0.2200 mL	1.1002 mL	2.2004 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (220.04 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2-ethoxy-1-naphthalenyl)carbonyl]amino]-3,3-dimethyl-7-oxo-, sodium salt, hydrate (1:1:1), (2S,5R,6R)-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo-, monosodium salt, monohydrate

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2-ethoxy-1-naphthalenyl)carbonyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, monohydrate, [2S-(2α,5α,6β)]-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2-ethoxy-1-naphthalenyl)carbonyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, monohydrate, (2S,5R,6R)-

Sodium nafcillin monohydrate

Sodium 6-(2-ethoxy-1-naphthamido)penicillanate monohydrate

Nafcillin sodium hydrate